Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 5/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15443961 | 0.80 | ADORA1 (0.35) | CYP2A6ADORA1DYRK1ADYRK1BBACE1 | |
| SCHEMBL8232610 | 0.77 | ADORA1 (0.33) | CYP2A6ADORA1BACE1PIK3R1PIK3CA | |
| SCHEMBL12174841 | 0.76 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL20764832 | 0.72 | HSD17B1 (0.44) | ESR1ESR2 | |
| SCHEMBL5033807 | 0.69 | ESR1 (0.50) | CYP2A6ADORA1BACE1ESR1ESR2 | |
| SCHEMBL19189171 | 0.69 | BACE1 (0.43) | CYP2A6ADORA1BACE1ATM | |
| SCHEMBL13028219 | 0.69 | GAA (0.41) | — | |
| SCHEMBL12757438 | 0.69 | ESR2 (0.38) | CYP2A6ESR1ESR2 | |
| SCHEMBL15263115 | 0.67 | ATM (0.39) | CYP2A6DYRK1ADYRK1BATM | |
| SCHEMBL12951370 | 0.67 | MAPT (0.39) | CYP2A6ATMSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2184994-B1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-12 | — | — | US | disclosed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8435996-B2 | Heterocycle-aryl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-11 | — | — | US | disclosed |
| EP-2184994-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009017818-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-1983831-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007087429-A2 | PHENYL AND PYRIDYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236481-A1 | HETEROCYCLE -ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | CYP2A6 248/4885ADORA1 858/4885DYRK1A 4328/4885 |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | NLRP3, CCR1, NLRP1 | CYP2A6 201/4885ADORA1 451/4885DYRK1A 2498/4885 |
| US-20100286103-A1 | HETEROCYCLE-ARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | AHR, NFATC1, ICOS | CYP2A6 248/4885ADORA1 858/4885DYRK1A 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.